ATE230600T1 - Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus - Google Patents

Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus

Info

Publication number
ATE230600T1
ATE230600T1 AT96930137T AT96930137T ATE230600T1 AT E230600 T1 ATE230600 T1 AT E230600T1 AT 96930137 T AT96930137 T AT 96930137T AT 96930137 T AT96930137 T AT 96930137T AT E230600 T1 ATE230600 T1 AT E230600T1
Authority
AT
Austria
Prior art keywords
pct
levels
thienotriazolediazepine
apolopoprotein
increase
Prior art date
Application number
AT96930137T
Other languages
German (de)
English (en)
Inventor
Herman Kempen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE230600T1 publication Critical patent/ATE230600T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96930137T 1995-09-09 1996-08-30 Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus ATE230600T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (1)

Publication Number Publication Date
ATE230600T1 true ATE230600T1 (de) 2003-01-15

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930137T ATE230600T1 (de) 1995-09-09 1996-08-30 Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus

Country Status (14)

Country Link
US (1) US5854238A (cg-RX-API-DMAC10.html)
EP (1) EP0853480B1 (cg-RX-API-DMAC10.html)
JP (1) JPH11512107A (cg-RX-API-DMAC10.html)
KR (1) KR19990044460A (cg-RX-API-DMAC10.html)
CN (1) CN1101680C (cg-RX-API-DMAC10.html)
AT (1) ATE230600T1 (cg-RX-API-DMAC10.html)
AU (1) AU725249B2 (cg-RX-API-DMAC10.html)
BR (1) BR9610390A (cg-RX-API-DMAC10.html)
CA (1) CA2230477A1 (cg-RX-API-DMAC10.html)
DE (1) DE69625696T2 (cg-RX-API-DMAC10.html)
DK (1) DK0853480T3 (cg-RX-API-DMAC10.html)
ES (1) ES2188783T3 (cg-RX-API-DMAC10.html)
TR (1) TR199800406T1 (cg-RX-API-DMAC10.html)
WO (1) WO1997009048A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CN102292341B (zh) * 2008-10-30 2014-09-10 环行医学有限责任公司 对apo a有活性的噻吩并三唑并二氮杂*衍生物
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EA202092635A1 (ru) 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
JPS50100096A (cg-RX-API-DMAC10.html) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
AU725249B2 (en) 2000-10-12
BR9610390A (pt) 1999-07-06
DE69625696D1 (de) 2003-02-13
CN1101680C (zh) 2003-02-19
EP0853480A1 (en) 1998-07-22
US5854238A (en) 1998-12-29
EP0853480B1 (en) 2003-01-08
ES2188783T3 (es) 2003-07-01
WO1997009048A1 (en) 1997-03-13
KR19990044460A (ko) 1999-06-25
DK0853480T3 (da) 2003-05-05
CN1195989A (zh) 1998-10-14
MX9801753A (es) 1998-08-30
CA2230477A1 (en) 1997-03-13
AU6930396A (en) 1997-03-27
TR199800406T1 (en) 1998-05-21
JPH11512107A (ja) 1999-10-19
DE69625696T2 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
DE69625696D1 (de) Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
TR199901276T2 (xx) Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
DE69528470D1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
CA2174494A1 (en) Benzofurans
IL143748A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
DK0865498T3 (da) Fremgangsmåde til fremstilling af substituerede arylmælkesyreholdige cyclodepsipeptider med 24 ringatomer
AU4080097A (en) Piperazino derivatives as neurokinin antagonists
ATE244712T1 (de) Piperazino-derivative als neurokininantagonisten
IL122606A (en) (S)-hydroxa-nitrile-lyase
DE69636393D1 (de) Montirelin zur verhinderung der schlafapnoe
AU6378994A (en) Plant promoter, microorganisms and plant cells containing a unit for the expression of a protein of interest comprising said promoter
GR3035237T3 (en) Algicide combination
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE69333302D1 (de) Mikroorganismen, ihre herstellung und verwendung
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
DE69213660D1 (de) Verwendung von 1-(beta-d-arabinofuranosyl)-5-propynyluracil zur senkung des serumcholesterins
AU4944996A (en) Dna fragment encoding d-amino acid oxidase
ES2139341T3 (es) Isocomarinas antitumorales.
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69814401D1 (de) 2,3-benzodiazepin-derivate
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
AU2003261230A1 (en) Apolipoprotein e stable folding intermediate and methods of use thereof
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0853480

Country of ref document: EP

REN Ceased due to non-payment of the annual fee